Details of the Drug

General Information of Drug (ID: DMCA9QP)

Drug Name

Papaverine

Synonyms

papaverine; Papaverin; Papanerine; Robaxapap; 58-74-2; Papanerin; Pavabid; Papaverina; Pavatym; 1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline; Cerespan; Papaverine [BAN]; Pavacot; Papaverina [Italian]; 6,7-Dimethoxy-1-veratrylisoquinoline; Papaverine Hcl; NSC 136630; UNII-DAA13NKG2Q; Isoquinoline, 6,7-dimethoxy-1-veratryl-; S-M-R; Papaverine (BAN); Pamelon; Chlorhydrate de papaverine; Qua bid; 1-(3,4-Dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline; 1-((3,4-Dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline; Alapav; Cardiospan; Cardoverina; Ceraspan; Cerebid; Delapav; Dilaves; Dispamil; Drapavel; Durapav; Dynovas; Forpavin; Genabid; Mesotina; Myobid; Pameion; Panergon; Papacon; Papalease; Papaversan; Pavacap; Pavacels; Pavacen; Pavagen; Pavarine; Pavatest; Pavatine; Paverolan; Paveron; Pavnell; Vasal; PAP H; Papavarine chlorhydrate; Papaverine chlorohydrate; Papaverine monohydrochloride; Papaverinium chloride; Pavabid Hp; RS 47; TNP00305; Alapav (TN); Albatran (TN); Artegodan (TN); Cardiospan (TN); Cardioverina (TN); Cepaverin (TN); Cerebid (TN); Cerespan (TN); Delapav (TN); Dicertan (TN); Dilaves (TN); Dispamil (TN); Drapavel (TN); Durapav (TN); Dynovas (TN); Forpaven (TN); Houde (TN); Mesotina (TN); Myobid (TN); Opdensit (TN); Optenyl (TN); Pameion (TN); Pamelon (TN); Panergon (TN); Papacon (TN); Papalease (TN); Papanerin-hcl; Papaversan (TN); Pavabid (TN); Pavacap (TN); Pavacen (TN); Pavadel (TN); Pavadyl (TN); Pavagen (TN); Pavakey (TN); Pavased (TN); Pavatest (TN); Paverina (TN); Paverolan (TN); Paveron (TN); Pavnell (TN); Qua bid (TN); Ro-Papav; Therapav (TN); Vasal (TN); Vaso-Pav; Vasospan (TN); Papanerin-hcl (TN); Papaverin-Hamelin (TN); Papital TR; Paptial TR; Ro-Papav (TN); Spasmo-Nit (TN); Vaso-Pav (TN); Pap-Kaps-150 (TN); Papital TR (TN); Paptial TR (TN); Isoquinoline,6,7-dimethoxy-1-veratryl-(8CI); Isoquinoline, 6,7-dimethoxy-1-veratryl-(8Cl); 1-[(3,4-Dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline; 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline; 1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline; 4-[(6,7-Dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene; 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline; 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXYISOQUINOLINE

Indication

Disease Entry	ICD 11	Status	REF
Spasm	MB47.3	Approved	[1]

Therapeutic Class

Vasodilator Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

339.4

Topological Polar Surface Area (xlogp)

3.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.5 - 2 hours [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 25.2554 micromolar/kg/day [3]
Unbound Fraction: The unbound fraction of drug in plasma is 0.073% [2]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1 L/kg [2]

Chemical Identifiers

Formula: C20H21NO4
IUPAC Name: 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
Canonical SMILES: COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
InChI: InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3
InChIKey: XQYZDYMELSJDRZ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4680
ChEBI ID: CHEBI:28241
CAS Number: 58-74-2
DrugBank ID: DB01113
TTD ID: D0NJ3V
VARIDT ID: DR00967
INTEDE ID: DR2299

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 4D (PDE4D)	TTSKMI8	PDE4D_HUMAN	Inhibitor	[4]
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Spasm

ICD Disease Classification

MB47.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phosphodiesterase 5A (PDE5A)	DTT	PDE5A	1.60E-01	-0.25	-0.99

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Papaverine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[23]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Papaverine and Midostaurin.	Acute myeloid leukaemia [2A60]	[23]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Papaverine and Idarubicin.	Acute myeloid leukaemia [2A60]	[23]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Papaverine and Arn-509.	Acute myeloid leukaemia [2A60]	[23]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Papaverine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[23]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Papaverine and Oliceridine.	Acute pain [MG31]	[24]
Ivabradine	DM0L594	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ivabradine.	Angina pectoris [BA40]	[23]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Dronedarone.	Angina pectoris [BA40]	[23]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Papaverine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[23]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Cilostazol.	Arterial occlusive disease [BD40]	[23]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Papaverine and Posaconazole.	Aspergillosis [1F20]	[23]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[23]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Papaverine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[23]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Papaverine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[23]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Papaverine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Papaverine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Papaverine and Retigabine.	Behcet disease [4A62]	[23]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Papaverine and Cariprazine.	Bipolar disorder [6A60]	[25]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Papaverine and Eribulin.	Breast cancer [2C60-2C6Y]	[23]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lapatinib.	Breast cancer [2C60-2C6Y]	[23]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Papaverine and Bosutinib.	Breast cancer [2C60-2C6Y]	[23]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Papaverine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[23]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Halothane.	Corneal disease [9A76-9A78]	[23]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Papaverine and Sevoflurane.	Corneal disease [9A76-9A78]	[23]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Papaverine and Probucol.	Coronary atherosclerosis [BA80]	[23]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Papaverine and Pasireotide.	Cushing syndrome [5A70]	[23]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Papaverine and Osilodrostat.	Cushing syndrome [5A70]	[23]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Papaverine and Isocarboxazid.	Depression [6A70-6A7Z]	[26]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Papaverine and Escitalopram.	Depression [6A70-6A7Z]	[23]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Papaverine and OPC-34712.	Depression [6A70-6A7Z]	[25]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Papaverine and Clomipramine.	Depression [6A70-6A7Z]	[23]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Papaverine and Doxepin.	Depression [6A70-6A7Z]	[23]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Papaverine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[23]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Papaverine and Deutetrabenazine.	Dystonic disorder [8A02]	[23]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Papaverine and Ingrezza.	Dystonic disorder [8A02]	[23]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Papaverine and Solifenacin.	Functional bladder disorder [GC50]	[23]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Papaverine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[23]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Papaverine and Procarbazine.	Hodgkin lymphoma [2B30]	[26]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Papaverine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Papaverine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[23]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Papaverine and ITI-007.	Insomnia [7A00-7A0Z]	[25]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Papaverine and Crizotinib.	Lung cancer [2C25]	[23]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Osimertinib.	Lung cancer [2C25]	[23]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Papaverine and Selpercatinib.	Lung cancer [2C25]	[23]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lumefantrine.	Malaria [1F40-1F45]	[23]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Papaverine and Halofantrine.	Malaria [1F40-1F45]	[23]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Papaverine and Hydroxychloroquine.	Malaria [1F40-1F45]	[23]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Papaverine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[23]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Papaverine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[23]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Vemurafenib.	Melanoma [2C30]	[23]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Papaverine and Panobinostat.	Multiple myeloma [2A83]	[23]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Papaverine and Siponimod.	Multiple sclerosis [8A40]	[27]
Fingolimod	DM5JVAN	Major	Increased risk of prolong QT interval by the combination of Papaverine and Fingolimod.	Multiple sclerosis [8A40]	[23]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Papaverine and Ozanimod.	Multiple sclerosis [8A40]	[28]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Papaverine and Romidepsin.	Mycosis fungoides [2B01]	[23]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Papaverine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[23]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Papaverine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[23]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Papaverine and Entrectinib.	Non-small cell lung cancer [2C25]	[23]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Papaverine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[23]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lofexidine.	Opioid use disorder [6C43]	[23]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Papaverine and Rucaparib.	Ovarian cancer [2C73]	[23]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Papaverine and Triclabendazole.	Parasitic worm infestation [1F90]	[23]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Papaverine and Safinamide.	Parkinsonism [8A00]	[26]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Papaverine and Rasagiline.	Parkinsonism [8A00]	[26]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Papaverine and Pimavanserin.	Parkinsonism [8A00]	[23]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Papaverine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[23]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lefamulin.	Pneumonia [CA40]	[23]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Papaverine and Degarelix.	Prostate cancer [2C82]	[23]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Papaverine and Enzalutamide.	Prostate cancer [2C82]	[23]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Papaverine and Relugolix.	Prostate cancer [2C82]	[23]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Papaverine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[25]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Papaverine and Quetiapine.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Papaverine and Aripiprazole.	Schizophrenia [6A20]	[25]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Papaverine and Iloperidone.	Schizophrenia [6A20]	[23]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Papaverine and Paliperidone.	Schizophrenia [6A20]	[25]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Papaverine and Molindone.	Schizophrenia [6A20]	[25]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Papaverine and Amisulpride.	Schizophrenia [6A20]	[23]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Papaverine and Asenapine.	Schizophrenia [6A20]	[23]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Papaverine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[23]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Papaverine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[23]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Papaverine and Pitolisant.	Somnolence [MG42]	[23]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Papaverine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[23]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Papaverine and Lenvatinib.	Thyroid cancer [2D10]	[23]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Papaverine and Cabozantinib.	Thyroid cancer [2D10]	[23]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Papaverine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[23]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Papaverine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[23]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Papaverine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[23]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Papaverine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[23]
-----------


⏷ Show the Full List of 92 DDI Information of This Drug

References

1	Drug information of Papaverine, 2008. eduDrugs.
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
5	Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
6	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
8	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
9	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
10	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
12	The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
13	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
14	Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
15	Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
16	The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
17	Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
18	cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
19	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
20	Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
21	Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
22	Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6033-6.
23	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
24	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
25	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
26	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
27	Cerner Multum, Inc. "Australian Product Information.".
28	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.